As healthcare undergoes one of its most volatile chapters in recent memory, some major developments signal a deeper reckoning with how America manages its medicines, its money, and its moral contract with the vulnerable.
Regulatory overreach rebuffed
A federal judge in Texas has vacated the FDA’s controversial rule that